CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1021-1026

  Iriyama, Noriyoshi ^a   Hatta, Yoshihiro ^a   Takeuchi, Jin ^a   Ogawa, Yoshiaki ^b   Ohtake, Shigeki ^c   Sakura, Toru ^d   Mitani, Kinuko ^e   Ishida, Fumihiro ^f   Takahashi, Masatomo ^g   Maeda, Tomoya ^h   Izumi, Tohru ⁱ   Sakamaki, Hisashi ^j   Miyawaki, Shuichi ^k   Honda, Sumihisa ^l   Miyazaki, Yasushi ^m   Taki, Tomohiko ⁿ   Taniwaki, Masafumi ⁿ   Naoe, Tomoki ^o  

^a NIHON UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

ⁱ TOCHIGI CANCER CENTER   (Japan)

^j TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^k Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^l NAGASAKI UNIVERSITY   (Japan)

^m NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

ⁿ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^o NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute myeloid leukemia with t(8 ; 21); CD56 antigen; Prognostic factor

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA WITH T(8 21); ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACUTE MYELOID LEUKEMIA WITH T(8 ;21); CD56 ANTIGEN; PROGNOSTIC FACTOR;

ADOLESCENT; ADULT; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84880937266     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.002     Document Type: Article

References (24)

1. Mason K.D., Juneja S.K., Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Rev 2006, 20:71-82.
2. Montesinos P., Rayon C., Vellenga E., Brunet S., Gonzalez J., Gonzalez M., et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011, 117:1799-1805.
3. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
4. Visani G., Bernasconi P., Boni M., Castoldi G.L., Ciolli S., Clavio M., et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia - analysis of 848 patients. Leukemia 2001, 15:903-909.
5. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998, 92:2322-2333.
6. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest oncology group/Eastern Cooperative oncology group study. Blood 2000, 96:4075-4083.
7. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
8. Kita K., Nakase K., Miwa H., Masuya M., Nishii K., Morita N., et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992, 80:470-477.
9. Porwit-MacDonald A., Janossy G., Ivory K., Swirsky D., Peters R., Wheatley K., et al. Leukemia-associated changes identified by quantitative flow cytometry. IV: CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996, 87:1162-1169.
10. Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L.W.M.M., et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993, 81:3083-3090.
11. Yang D.H., Lee J.J., Mun Y.C., Shin H.J., Kim Y.K., Cho S.H., et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8;21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:1-5.
12. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997, 90:1643-1648.
13. Nakase K., Bradstock K., Sartor M., Gottlieb D., Byth K., Kita K., et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia 2000, 14:163-168.
14. Miyawaki S., Sakamaki H., Ohtake S., Emi N., Yagasaki F., Mitani K., et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer 2005, 104:2726-2734.
15. Löwenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
16. Raspadori D., Damiani D., Michieli M., Stocchi R., Gentili S., Gozzetti A., et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica 2002, 87:1135-1140.
17. Raspadori D., Damiani D., Lenoci M., Rondelli D., Testoni N., Nardi G., et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001, 15:1161-1164.
18. Byrd J.C., Dodge R.K., Carroll A., Baer M.R., Edwards C., Stamberg J., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17:3767-3775.
19. Miyawaki S., Ohtake S., Fujisawa S., Kiyoi H., Shinagawa K., Usui N., et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 2011, 117:2366-2372.
20. Ohtake S., Miyawaki S., Fujita H., Kiyoi H., Shinagawa K., Usui N., et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011, 117:2358-2365.
21. Park S.H., Chi H.S., Min S.K., Park B.G., Jang S., Park C.J. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011, 35:1376-1383.
22. Wakita S., Yamaguchi H., Miyake K., Mitamura Y., Kosaka F., Dan K., et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2011, 25:1423-1432.
23. De J., Zanjani R., Hibbard M., Davis B.H. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. Am J Clin Pathol 2007, 128:550-557.
24. Miyawaki S. Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia study group. Int J Hematol 2012, 96:171-177.